BNP Paribas Financial Markets’s Immunic IMUX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $352K | Buy |
22,909
+10,724
| +88% | +$132K | ﹤0.01% | 3947 |
|
|
2026
Q1 | $135K | Buy |
12,185
+12,182
| +406,067% | +$109K | ﹤0.01% | 4225 |
|
|
2025
Q4 | $14 | Hold |
3
| – | – | ﹤0.01% | 5683 |
|
|
2025
Q3 | $23 | Hold |
3
| – | – | ﹤0.01% | 5497 |
|
|
2025
Q2 | $18 | Buy |
3
+2
| +200% | +$18 | ﹤0.01% | 5396 |
|
|
2025
Q1 | $7 | Hold |
1
| – | – | ﹤0.01% | 5347 |
|
|
2024
Q4 | $6 | Hold |
1
| – | – | ﹤0.01% | 5372 |
|
|
2024
Q3 | $10 | Hold |
1
| – | – | ﹤0.01% | 4120 |
|
|
2024
Q2 | $7 | Hold |
1
| – | – | ﹤0.01% | 4021 |
|
|
2024
Q1 | $8 | Hold |
1
| – | – | ﹤0.01% | 4013 |
|
|
2023
Q4 | $9 | Sell |
1
-1
| -50% | -$12 | ﹤0.01% | 3983 |
|
|
2023
Q3 | $32 | Hold |
2
| – | – | ﹤0.01% | 3876 |
|
|
2023
Q2 | $43 | Buy |
+2
| New | +$34 | ﹤0.01% | 3877 |
|
|
2023
Q1 | – | Hold |
0
| – | – | – | 3840 |
|
|
2022
Q4 | – | Sell |
-9
| Closed | -$245 | – | 4021 |
|
|
2022
Q3 | $297 | Sell |
9
-177
| -95% | -$7.41K | ﹤0.01% | 4573 |
|
|
2022
Q2 | $6.45K | Sell |
186
-43
| -19% | -$2.75K | ﹤0.01% | 3798 |
|
|
2022
Q1 | $25.8K | Sell |
229
-493
| -68% | -$57.1K | ﹤0.01% | 3689 |
|
|
2021
Q4 | $69.1K | Buy |
722
+367
| +103% | +$33.1K | ﹤0.01% | 3681 |
|
|
2021
Q3 | $31.4K | Buy |
355
+188
| +113% | +$18.5K | ﹤0.01% | 3603 |
|
|
2021
Q2 | $20.5K | Buy |
167
+36
| +27% | +$4.98K | ﹤0.01% | 3525 |
|
|
2021
Q1 | $20.9K | Buy |
131
+29
| +28% | +$4.92K | ﹤0.01% | 3749 |
|
|
2020
Q4 | $15.6K | Sell |
102
-24
| -19% | -$4.31K | ﹤0.01% | 3880 |
|
|
2020
Q3 | $23.4K | Buy |
126
+113
| +869% | +$18.5K | ﹤0.01% | 3780 |
|
|
2020
Q2 | $1.56K | Buy |
13
+12
| +1,200% | +$1.22K | ﹤0.01% | 4185 |
|
|
2020
Q1 | $30 | Hold |
1
| – | – | ﹤0.01% | 4255 |
|
|
2019
Q4 | $48 | Sell |
1
-18
| -95% | -$1.5K | ﹤0.01% | 4363 |
|
|
2019
Q3 | $1.92K | Hold |
19
| – | – | ﹤0.01% | 4366 |
|
|
2019
Q2 | $2.2K | Sell |
19
-2
| -10% | -$263 | ﹤0.01% | 4312 |
|
|
2019
Q1 | $1.63K | Buy |
21
+17
| +425% | +$1.49K | ﹤0.01% | 4126 |
|
|
2018
Q4 | $273 | Sell |
4
-1
| -20% | -$117 | ﹤0.01% | 4063 |
|
|
2018
Q3 | $530 | Hold |
5
| – | – | ﹤0.01% | 4343 |
|
|
2018
Q2 | $13.2K | Buy |
5
+3
| +150% | +$6.93K | ﹤0.01% | 3668 |
|
|
2018
Q1 | $6.3K | Hold |
2
| – | – | ﹤0.01% | 4041 |
|
|
2017
Q4 | $5.51K | Hold |
2
| – | – | ﹤0.01% | 4061 |
|
|
2017
Q3 | $4.74K | Hold |
2
| – | – | ﹤0.01% | 3985 |
|
|
2017
Q2 | $2.72K | Hold |
2
| – | – | ﹤0.01% | 4078 |
|
|
2017
Q1 | $3.75K | Buy |
2
+1
| +100% | +$1.83K | ﹤0.01% | 3371 |
|
|
2016
Q4 | $900 | Sell |
1
-3
| -75% | -$6.57K | ﹤0.01% | 4024 |
|
|
2016
Q3 | $9.8K | Buy |
4
+2
| +100% | +$4.93K | ﹤0.01% | 3174 |
|
|
2016
Q2 | $5.75K | Buy |
2
+1
| +100% | +$3.29K | ﹤0.01% | 3206 |
|
|
2016
Q1 | $3.31K | Sell |
1
-12
| -92% | -$41.7K | ﹤0.01% | 2337 |
|
|
2015
Q4 | $60.8K | Buy |
13
+3
| +30% | +$9.79K | ﹤0.01% | 2672 |
|
|
2015
Q3 | $15.9K | Buy |
10
+7
| +233% | +$35K | ﹤0.01% | 3357 |
|
|
2015
Q2 | $29.4K | Buy |
+3
| New | +$28.6K | ﹤0.01% | 2814 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 3332 |
|
|
2014
Q4 | – | Hold |
0
| – | -$3.65K | – | 2567 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 3883 |
|
Other funds holding IMUX
VCM
SCM
PBM
VFT
QC
BNP Paribas Financial Markets's IMUX Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its Immunic (IMUX) stake by 88% in Q2 2026, buying an estimated $132K and bringing the position to 22,909 shares worth $352K. The position accounts for ﹤0.01% of the portfolio, ranked #3947.
BNP Paribas Financial Markets first reported a position in IMUX in Q2 2015 and has held it in 43 quarters since. 30 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.
- BNP Paribas Financial Markets held 22,909 shares of Immunic worth $352K as of Q2 2026.
- BNP Paribas Financial Markets bought 10,724 Immunic shares in Q2 2026, an estimated $132K.
- Immunic made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3947 holding.
- BNP Paribas Financial Markets first reported a position in Immunic in Q2 2015 and has held it in 43 quarters since.
- 30 funds tracked by Wall St. Rank held Immunic as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.